X

Johnson & Johnson Expands ACUVUE Manufacturing With $1B Florida Investment

The project includes advanced manufacturing and packaging technologies, plus a new distribution facility expected to be fully operational in 2028. Photo courtesy of Johnson & Johnson.

The project includes advanced manufacturing and packaging technologies, plus a new distribution facility expected to be fully operational in 2028. Photo courtesy of Johnson & Johnson.

The Jacksonville investment will expand ACUVUE contact lens manufacturing, packaging and distribution capacity as part of J&J’s broader US manufacturing push.

Johnson & Johnson (J&J) is expanding its US Vision manufacturing and supply chain footprint through a more than $1 billion investment in Jacksonville, Florida.

The project includes advanced manufacturing and packaging technologies, along with a new distribution facility. The upgrades will expand production capacity for ACUVUE, J&J’s contact lens brand.

Contact lenses are regulated medical devices worn on the eye. That means manufacturing, packaging and distribution must meet strict quality and safety standards.

Construction is already underway, and J&J expects the new facility to be fully operational in 2028. The expansion will help serve more than 40 million patients in the US and globally.

Xtalks Insights

Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.

What topics would you like to hear more about?

Select all that apply.

Want to get even more specific?

Help us narrow down the sub-topics that you're most interested in.

Thank you!

For webinars, videos, podcasts and more from Xtalks, join our community today.

BECOME A FREE MEMBER

The Jacksonville project is part of J&J’s $55 billion commitment to US manufacturing, research and development and technology through early 2029.

In February 2026, the company announced more than $1 billion for a cell therapy facility in Pennsylvania, which is expected to support 500 biomanufacturing roles and 4,000 construction jobs.

Florida has also seen recent investment in life sciences. Novartis recently announced plans for a 35,000-square-foot radioligand therapy site in Winter Park. The facility is expected to open in 2029 as one of five Novartis radioligand therapy manufacturing sites in the US. Radioligand therapy links tumor-seeking molecules with radioactive payloads to help target cancer cells directly.

State funding is also supporting cancer research in Florida. For fiscal year 2025-26, the Florida Department of Health made $60 million available through the Florida Cancer Innovation Fund. The funding supports research efforts, including clinical trials, generic drug repurposing and nutrition-based prevention strategies.

J&J is also building on its long-standing presence in Jacksonville, where it has operated since 1981. The company currently manufactures more than 1.7 billion ACUVUE contact lenses annually for US patients and has more than 1.5 million square feet of manufacturing, research, distribution and operations facilities in Florida.

The investment supports 3,500 Jacksonville employees and builds on Johnson & Johnson’s approximately $6 billion annual economic impact in the state.


If you want your company to be featured on Xtalks.com, please email [email protected].